facebook
eISSN: 2084-9893
ISSN: 0033-2526
Dermatology Review/Przegląd Dermatologiczny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
6/2019
vol. 106
 
Share:
Share:
abstract:
Review article

An analysis of selected factors influencing the efficacy of psoriasis therapy

Beniamin O. Grabarek
1, 2
,
Jakub Krzaczyński
3
,
Barbara Strzałka-Mrozik
3
,
Dominika Wcisło-Dziadecka
4

  1. Department of Histology, Cytophysiology and Embryology, Faculty of Medicine, University of Technology, Zabrze, Poland/Katedra Histologii, Cytofizjologii i Embriologii, Wydział Nauk Medycznych im. Profesora Zbigniewa Religi, Wyższa Szkoła Techniczna, Zabrze, Polska
  2. Center of Oncology, M. Skłodowska-Curie Memorial Institute, Krakow Branch, Poland/Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie, Państwowy Instytut Badawczy, Oddział w Krakowie, Polska
  3. Department of Molecular Biology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Poland/Katedra i Zakład Biologii Molekularnej, Wydział Nauk Farmaceutycznych w Sosnowcu, Śląski Uniwersytet Medyczny w Katowicach, Polska
  4. Department of Cosmetology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Poland/Katedra Kosmetologii, Wydział Nauk Farmaceutycznych w Sosnowcu, Śląski Uniwersytet Medyczny w Katowicach, Polska
Dermatol Rev/Przegl Dermatol 2019, 106, 603–614
Online publish date: 2020/02/07
View full text Get citation
 
PlumX metrics:
Psoriasis is a chronic disease characterized by a complex immunopathogenesis of recurrent inflammation of the skin. The course and intensity of the disease depend on many genetic, environmental and behavioural factors. The treatment of psoriasis includes a therapy with ultraviolet radiation, methotrexate, cyclosporine A, keratolytic preparations, tar, anthralin, glucocorticoids, calcineurin inhibitors, retinoids, and vitamin D3 derivatives. A new class of biological drugs (personalized therapy) that was introduced includes cytokine inhibitors, i.e. TNF – etanercept, adalimumab, infliximab, certolizumab pegol, golimumab; IL-12/23 – ustekinumab; IL-17 – secukinumab, ixekizumab, brodalumab. Effective treatment of psoriasis is a challenge. It is an important matter in anti-cytokine therapy to determine the influence of factors such as age, sex, environmental factors, viral and bacterial infections, an occurrence of comorbidities, individual rate of drug metabolism, and pharmacologic interactions of additionally taken drugs. The influence of many different factors translates into obtaining a heterogeneous adequate response to molecularly targeted treatments.
keywords:

pharmacotherapy of psoriasis, personalized therapy, individual factor



Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.